Successful treatment of neurocysticercosis with albendazole desensitization.

Asian Pac J Allergy Immunol

Department of Internal Medicine; Division of Rheumatology, Allergy and Clinical Immunology, University of California Davis, School of Medicine, Sacramento, CA, USA.

Published: June 2024

Background: Neurocysticercosis is a growing public health problem in the United States. Albendazole is a mainstay of medical therapy for neurocysticercosis, and here we present a case of hypersensitivity to albendazole leading to life-threatening disease progression.

Objective: To report the first successful albendazole desensitization protocol.

Methods: An oral albendazole 12-step desensitization protocol was developed, starting with 0.001 mg and progressing at 15 minutes intervals. Dosage for each subsequent step was as follows: 0.003 mg, 0.01 mg, 0.03 mg, 0.1 mg, 0.3 mg, 1 mg, 3 mg, 10 mg, 30 mg, 100 mg, 300mg.

Results: The patient rapidly improved from a symptomatic standpoint, and repeat MRI showed a dramatic improvement in lesions.

Conclusions: This successful desensitization protocol to albendazole can be of value to other patients with history suggestive of IgE-mediated allergy needing treatment for parasitic infections.

Download full-text PDF

Source
http://dx.doi.org/10.12932/AP-191020-0983DOI Listing

Publication Analysis

Top Keywords

albendazole desensitization
8
desensitization protocol
8
albendazole
6
successful treatment
4
treatment neurocysticercosis
4
neurocysticercosis albendazole
4
desensitization
4
desensitization background
4
background neurocysticercosis
4
neurocysticercosis growing
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!